<DOC>
	<DOCNO>NCT00750126</DOCNO>
	<brief_summary>To assess engraftment hematopoietic stem cell follow reduced-intensity condition child present solid tumor hematological malignancy evaluate post-transplantation chimerism hematological reconstitution . To study acute and/or chronic graft-versus-host reaction ( incidence severity ) immune reconstitution , post-transplantation To study effectiveness protocol tumor response . To study overall survival .</brief_summary>
	<brief_title>Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Primary criterion - Hematological reconstitution chimerism post-transplantation Secondary criterion - Adverse effect , graft-related mortality D90 12 month , incidence severity acute and/or chronic GVH reaction - Analysis variation post-transplantation immunological function profile - Median duration response therapy-responsive patient median duration stability stabilize patient</detailed_description>
	<mesh_term>Hematologic Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients age less 20 year old Lansky score &gt; 60 % Life expectancy great 2 month Diagnoses : 3 Solid tumor hematological malignancy remain unresponsive reference strategy accord French best practice pediatrics . 4 Malignancies allografting recognize indication contraindicate myeloablative conditioning . Usual criterion allogeneic graft ( pregraft profile ) Having HLAidentical sibling donor HLAA , HLAB HLADR antigens HLA mismatch one antigen , 10/10 phenoidentical donor , compatible cord blood . Signed informed consent Patient present rapidlyprogressive malignancy In case potential donor relate , sibling present contraindication hematopoietic stem cell donation Unable sufficiently understand treatment consequence , even explanation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Allograft</keyword>
	<keyword>Children</keyword>
	<keyword>malignancy</keyword>
	<keyword>Reduced Intensity Conditioning</keyword>
	<keyword>Fludarabin</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>